A safety and efficacy of 12 cycles of IFN-free, DAAS-based therapies (SOVALDI™) in HIV/HCV-coinfected patients with Chronic Kidney Disease
Latest Information Update: 04 Mar 2016
Price :
$35 *
At a glance
- Drugs Sofosbuvir (Primary)
- Indications Hepatitis C; HIV infections
- Focus Adverse reactions; Therapeutic Use
- 04 Mar 2016 New trial record